Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome-Reference-Cited by-同舟云学术

Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2V617F positive, del(5)(q13q33) myelodysplastic syndrome

Published:2006-09-21 Issue:11 Volume:20 Page:2063-2064
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Mesa R A,Tefferi A,Li C-Yang,Steensma D P

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2404398.pdf

Reference5 articles.

1. List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557.

2. Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006; 108: 1158–1164.

3. Delima M, Ghaddar H, Pierce S, Estey E . Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996; 93: 89–95.

4. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649.

5. Ingram W, Lea NC, Cervera J, Germing U, Fenaux P, Cassinat B et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia 2006; 20: 1319–1321.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How We Manage Myelofibrosis Candidates for Allogeneic Stem Cell Transplantation;Cells;2022-02-05

2. Loss of 5q in myeloid malignancies – A gain in understanding of biological and clinical consequences;Blood Reviews;2021-03

3. Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study;Haematologica;2018-08-31

4. Innovative strategies for adverse karyotype acute myeloid leukemia;Current Opinion in Hematology;2017-03

5. Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy;OncoTargets and Therapy;2014-06